ONO 3708

Subscribe to Selected New Research on ONO 3708

21 relevant articles (2 outcomes, 2 trials/studies) found for this Bio-Agent

Description: structure given in first source; thromboxane A2 antagonist

Also Known As:

(9,11)(11,12)-dideoxa-9 alpha,11 alpha-dimethylmethano-11,12-methano-13,14-dihydro-13-aza-14-oxo-15-cyclopentyl-16,17,18,19,20-pentanor-15-epi-TXA2; (9,11),(11,12)-dideoxa-9,11-dimethylmethano-11,12-methano-13,14-dihydro-13-azo-14-oxo-15-cyclopentyl-16,17,18,19,20-pentanor-15-epithromboxane A2; ONO-3708; 5-Heptenoic acid, 7-(3-((cyclopentylhydroxyacetyl)amino)-6,6-dimethylbicyclo(3.1.1)hept-2-yl)-, (1S-(1alpha,2beta(Z),3alpha(S*),5alpha))-

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13324

Fatty Acids: 4669

Unsaturated Fatty Acids: 2223

Eicosanoids: 1154

Arachidonic Acids: 78

Thromboxanes: 116

Thromboxane A2: 1257

ONO 3708: 21

Biological Factors: 871

Inflammation Mediators: 486

Related Diseases

1.	Shock 05/01/1989 - "These results suggest that ONO 3708, the antagonist of TXA2 receptor, has beneficial effects during endotoxin shock, at least in part by inhibiting platelet aggregation." 05/01/1989 - "Protective effects of ONO 3708, a new thromboxane A2 receptor antagonist, during experimental endotoxin shock." 09/01/1989 - "These results suggest that role of thromboxane A2 on the cardiovascular response during endotoxin shock is played only on pulmonary vascular changes, and ONO 3708 has a beneficial effect at least during the early phase of endotoxin shock." 09/01/1989 - "The effects of ONO 3708, a new thromboxane A2 receptor antagonist, on cardiovascular and airway responses, at an early phase during endotoxin shock were investigated in anesthetized dogs" 09/01/1989 - "The effects of ONO 3708, a new thromboxane receptor antagonist, on cardiovascular response during the early phases of endotoxin shock in anesthetized dogs]" Order ALL the reference details at left...
2.	Thrombocytopenia (Thrombopenia) 05/01/1989 - "Treatment with ONO 3708, 1 mg/100 g i.v., significantly improved the survival rate of rats in endotoxin shock from 38 to 72% at 24 hr and from 27 to 61% at 48 hr. ONO 3708 significantly attenuated endotoxin-induced thrombocytopenia, but not leukopenia" Order ALL the reference details at left...
3.	Necrosis 02/15/1996 - "Pretreatment with OKY 046 and ONO 3708 significantly improved survival, decreased the tissue water content, and lowered the levels of serum transaminases and the extent of histological liver necrosis compared with the control group" Order ALL the reference details at left...
4.	Leukopenia 05/01/1989 - "Treatment with ONO 3708, 1 mg/100 g i.v., significantly improved the survival rate of rats in endotoxin shock from 38 to 72% at 24 hr and from 27 to 61% at 48 hr. ONO 3708 significantly attenuated endotoxin-induced thrombocytopenia, but not leukopenia" Order ALL the reference details at left...
5.	Ischemia 02/15/1996 - "In group III, ONO 3708 (10 mg/kg, intravenous) was given 5 min before ischemia" 01/01/1995 - "ONO 3708 (200 micrograms/kg/min) was initiated 60 min before induction of ischemia and continued throughout the experiment" 11/01/1994 - "Mongrel dogs weighing from 10 to 15 kg were divided into three groups: a control group, a group with induced liver ischemia and subsequent reperfusion, and a group that received ONO 3708 and then underwent induced liver ischemia and subsequent reperfusion" 11/01/1994 - "In this study the effects of the thromboxane A2 receptor antagonist ONO 3708 on ischemia and subsequent reperfusion in the dog liver was evaluated" 01/01/1995 - "Thromboxane A2 receptor antagonist (ONO 3708) protects from liver damage induced by cholestasis and ischemia-reperfusion." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Prostaglandin H2 Thromboxane A2 Receptors
2.	ozagrel
3.	Transaminases
4.	Thromboxane Receptors (Thromboxane Receptor)
5.	Thromboxane A2 (A2, Thromboxane)
6.	Epoprostenol (Prostacyclin)
7.	Indomethacin (Indometacin)
8.	prostaglandin endoperoxide receptor
9.	Oleic Acid (Oleate)
10.	Thromboxane-A Synthase

Best Treatments:
Research Summary Report
on Shock

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1190 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>